GSA Capital Partners’s Carisma Therapeutics CARM Stock Holding History

GSA Capital Partners’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,431	Closed	-$80K	–	1499
2022 Q3	$80K	Buy	+9,431	New	+$128K	0.01%	1387
2021 Q3	–	Sell	-646	Closed	-$60K	–	1457
2021 Q2	$60K	Buy	646 +94	+17%	+$6K	0.01%	1271
2021 Q1	$29K	Sell	552 -6,821	-93%	-$322K	﹤0.01%	1040
2020 Q4	$199K	Buy	7,373 +6,509	+753%	+$165K	0.03%	995
2020 Q3	$24K	Sell	864 -4,696	-84%	-$93.9K	﹤0.01%	1212
2020 Q2	$80K	Buy	+5,560	New	+$75K	0.04%	507
2020 Q1	–	Sell	-739	Closed	-$15K	–	1090
2019 Q4	$15K	Buy	+739	New	+$17K	﹤0.01%	1385
2017 Q2	–	Sell	-4,695	Closed	-$207K	–	1695
2017 Q1	$207K	Buy	+4,695	New	+$196K	0.01%	1555

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BWA

Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GSA Capital Partners's CARM Position: Q4 2022 in Review

GSA Capital Partners sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 9,431 shares — an estimated $80K sold.

GSA Capital Partners first reported a position in CARM in Q1 2017 and held it in 8 quarters. The position peaked at $207K in Q1 2017. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

GSA Capital Partners reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 9,431 Carisma Therapeutics shares in Q4 2022, an estimated $80K.
GSA Capital Partners first reported a position in Carisma Therapeutics in Q1 2017 and held it in 8 quarters.
GSA Capital Partners's Carisma Therapeutics position peaked at $207K in Q1 2017.
70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.